Physician profile
Thomas Sorbera
NPI 1649382342
$7,905.70
in general payments reported to CMS, 2019-2025
38 companies · $2,194 in 2025
The $2,194 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,748 · 2020: $503 · 2021: $1,048 · 2022: $815 · 2023: $184 · 2024: $414 · 2025: $2,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Travel and Lodging: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.74 |
| Travel and Lodging | $1,066.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $2,689.50 | 2019-2022 | |
| Procept Biorobotics Corporation | $1,413.87 | 2019-2025 | |
| Boston Scientific Corporation | $1,380.93 | 2019-2025 | Ams 700, Rezum Generator, General - Kidney Stone Disease |
| Dornier Medtech America, INC | $195.09 | 2019-2022 | |
| Allergan, INC. | $193.99 | 2019-2022 | |
| Zyla Life Sciences, INC. | $193.44 | 2019-2020 | |
| Neotract INC. | $151.19 | 2019-2020 | |
| Biotissue Holdings INC. | $148.38 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $139.98 | 2019-2024 | Keytruda |
| Intuitive Surgical, INC. | $119.63 | 2025 | |
| Astellas Pharma US INC | $112.05 | 2019-2021 | |
| Janssen Biotech, INC. | $107.88 | 2020-2022 | |
| Rigicon,INC. | $101.59 | 2023 | Rigi10 Malleable Penile Prosthesis |
| Healthtronics Stone Solutions, LLC | $83.90 | 2019-2020 | |
| Smith+Nephew, INC. | $77.12 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $76.05 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $62.10 | 2023-2025 | Gemtesa, Orgovyx |
| Medtronic, INC. | $58.36 | 2025 | Interstim |
| Myovant Sciences INC. | $57.54 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $55.97 | 2023-2025 | Bard Urinary Drainage Bag |
| Angiodynamics, INC. | $54.66 | 2019 | |
| Abbvie INC. | $51.00 | 2020-2024 | |
| Dendreon Pharmaceuticals LLC | $45.55 | 2020-2021 | |
| Teleflex LLC | $37.45 | 2025 | Barrigel |
| Isoray, INC | $37.14 | 2021 | |
| Endo USA, INC. | $34.65 | 2024-2025 | Xiaflex |
| Axonics, INC. | $28.26 | 2020-2023 | Axonics |
| Urovant Sciences INC | $24.62 | 2022 | |
| Karl Storz Endoscopy-America | $24.20 | 2019 | |
| Travere Therapeutics, INC. | $21.48 | 2021 | |
| Palette Life Sciences, INC. | $19.70 | 2022 | |
| Pfizer INC. | $18.87 | 2020 | |
| Verity Pharmaceuticals INC. | $16.96 | 2022 | |
| Covidien LP | $16.26 | 2020 | |
| Tolmar, INC. | $15.97 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.40 | 2022 | |
| Accord Healthcare, INC. | $13.41 | 2022 | |
| Endo Pharmaceuticals INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sorbera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.